ReviewAlzheimer's & dementia : the journal of the Alzheimer's Association2025
Paving the way for Alzheimer's disease blood-based biomarkers in primary care.
Review in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Guideline
- Facing Dementia in Primary Care: A Process Evaluation of a Multicomponent Practice Change Intervention to Improve Dementia Diagnosis in General Practice.International journal of environmental research and public health · 2026Article
- Human biomarker navigator.iMeta · 2026Review
- Dementia diagnostic deserts: workforce and geographic inequities in the diagnostic pathway for cognitive impairment.Health affairs scholar · 2026Article
- Contextualizing Blood-Based Biomarkers for Dementia Globally.Journal of neurochemistry · 2026Review
- Predictive Biomarkers for Asymptomatic Adults: Opportunities, Risks, and Guidance for General Practice.Diagnostics (Basel, Switzerland) · 2026Review
- Translating blood-based biomarkers into Alzheimer's disease clinical practice: screening, diagnosis, and longitudinal monitoring.Frontiers in aging neuroscience · 2026Review
- Alzheimer's disease plasma biomarkers are associated with cognitive performance among Hispanic/Latino adults.Communications medicine · 2025Article
- Towards pharmacological prevention of Alzheimer disease.Nature reviews. Neurology · 2025Review
- Human herpes viruses are associated with steeper age-dependent increases of serum biomarkers for dementia in cognitively unimpaired women.Scientific reports · 2025Article
- Implementing early detection of cognitive impairment in primary care to improve care for older adults.Journal of internal medicine · 2025Review
- Paving the way for Alzheimer's disease blood-based biomarkers in primary care.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Digital cognition plus plasma p-Tau217 and Aβ42/40 powerfully predict Alzheimer's progression.Alzheimer's & dementia (Amsterdam, Netherlands)Article
- Evaluation of self-mediated alternatives for risk testing education and return of results (eSMARTER) study: A randomized study of methods for returningAlzheimer's & dementia (New York, N. Y.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Blood-based biomarkers (BBBMs) for Alzheimer's disease (AD) have the potential to revolutionize the detection and management of cognitive impairment. AD BBBMs are not currently recommended for use in primary care but may soon be as research demonstrates their clinical utility for differential diagnosis and patient management. To prepare for the incorporation of AD BBBMs into primary care, several practical challenges must be addressed. Here, we describe four immediate challenges: (1) preparing primary care providers to order and disclose AD BBBMs, (2) expanding the dementia-capable workforce, (3) ensuring equitable uptake of AD BBBM testing, and (4) securing access to AD treatment. We conclude by discussing future directions and challenges for use of AD BBBMs in primary care, including screening for preclinical AD and dementia detection algorithms. HIGHLIGHTS: Alzheimer's disease (AD) blood-based biomarkers (BBBMs) may be well suited for primary care. Many changes are needed to prepare the workforce and ensure patient access. Paving the way for AD BBBMs in primary care will require a multi-pronged approach.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.